Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy

被引：3

作者：

Kuroda, Junya ^{[1
]}

Mizutani, Shinsuke ^{[1
]}

Shimura, Yuji ^{[1
]}

Maegawa, Saori ^{[1
]}

Nagoshi, Hisao ^{[1
]}

Chinen, Yoshiaki ^{[1
]}

Tatekawa, Shotaro ^{[1
]}

Tsukamoto, Taku ^{[1
]}

Mizuno, Yoshimi ^{[1
]}

Yamamoto-Sugitani, Mio ^{[1
]}

Kobayashi, Tsutomu ^{[1
]}

Matsumoto, Yosuke ^{[1
]}

Horiike, Shigeo ^{[1
]}

Taniwaki, Masafumi ^{[1
]}

机构：

[1] Kyoto Prefectural Univ Med, Dept Med, Div Hematol & Oncol, Kamigyo Ku, Kyoto 6028566, Japan

来源：

ANNALS OF HEMATOLOGY | 2015年 / 94卷 / 04期

关键词：

RESISTANCE;

D O I：

10.1007/s00277-014-2214-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：687 / 689

页数：3

共 50 条

[1] Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy
Junya Kuroda
Shinsuke Mizutani
Yuji Shimura
Saori Maegawa
Hisao Nagoshi
Yoshiaki Chinen
Shotaro Tatekawa
Taku Tsukamoto
Yoshimi Mizuno
Mio Yamamoto-Sugitani
Tsutomu Kobayashi
Yosuke Matsumoto
Shigeo Horiike
Masafumi Taniwaki
Annals of Hematology, 2015, 94 : 687 - 689
[2] Subcutaneous Bortezomib In Multiple Myeloma
Hoy, Sheridan M.
DRUGS, 2013, 73 (01) : 45 - 54
[3] Bortezomib therapy of multiple myeloma
Anderson, K.
EJC SUPPLEMENTS, 2008, 6 (12): : 15 - 16
[4] INTRAVENOUS SWITCHING OF BORTEZOMIB CAN OVERCOME RESISTANCE AFTER SUBCUTANEOUS ADMINSTRATION IN MULTIPLE MYELOMA PATIENTS
Gozzetti, A.
Candi, V.
Papini, G.
Defina, M.
Schiattone, L.
Bocchia, M.
HAEMATOLOGICA, 2014, 99 : 651 - 652
[5] Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
Moreau, Philippe
Coiteux, Valerie
Hulin, Cyrille
Leleu, Xavier
van de Velde, Helgi
Acharya, Milin
Harousseau, Jean-Luc
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (12): : 1908 - 1911
[6] Dermatosis toxica and phlebitis - adverse effects in a patient with multiple myeloma after bortezomib administration subcutaneous and intravenous
Piribauer, M.
Tomka, M.
Weiss, H.
Siebert, F.
Oncology Research and Treatment, 2015, 38 : 240 - 241
[7] Efficacy and safety of subcutaneous bortezomib versus intravenous bortezomib in patients with multiple myeloma: a systematic review and meta-analysis
Zhang, Shilong
Li, Jing
Liu, Peng
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (02): : 445 - +
[8] Bortezomib Combination Therapy in Multiple Myeloma
Kapoor, Prashant
Ramakrishnan, Vijay
Rajkumar, S. Vincent
SEMINARS IN HEMATOLOGY, 2012, 49 (03) : 228 - 242
[9] Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
Hu, Bin
Zhou, Quan
Wu, Tao
Zhuang, Lan
Yi, Liping
Cao, Jinxia
Yang, Xin
Wang, Jun
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (04) : 329 - 338
[10] Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients:a Meta-analysis
牟时代
艾利莎
秦铀
胡豫
Current Medical Science, 2018, 38 (01) : 43 - 50

← 1 2 3 4 5 →